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Abstract of the Dissertation 
 
Relationship between Serum Biomarkers and Three-Month Outcomes 
following Pediatric Traumatic Brain Injury (TBI) 
by 
Alicia Leanne Janos 
Doctor of Philosophy in Psychology 
Washington University in St. Louis, 2015 
Professor Desirée A. White, Chair 
 
With more than 475,000 cases annually, traumatic brain injury (TBI) is the leading cause of 
morbidity and mortality in children (Langlois, Rutland-Brown, & Thomas, 2005). Promising 
new tools for the prediction of functional outcomes following pediatric TBI are biomarkers of 
brain injury that can be detected in blood serum. The most commonly studied biomarkers, 
S100β, neuron-specific enolase (NSE), and myelin basic protein (MBP), have myriad limitations 
which preclude their use in clinical care (Geyer, Ulrich, Gräfe, Stach, & Till, 2009; Giacoppo et 
al., 2012; Savola et al., 2003). In the present study, serum concentrations of two novel 
biomarkers of brain injury (i.e., ubiquitin carboxy-terminal hydrolase-L1, UCH-L1; glial 
fibrillary acidic protein, GFAP) were collected 24 hours following severe TBI in 30 children 
aged 1 month to 17 years. These 24-hour biomarkers were examined in relation to functional 
outcomes 3 months following TBI. Functional outcomes reflected global, intellectual (IQ), and 
neuropsychological (processing speed, working memory, episodic memory, executive function) 
function. Results indicated that 24-hour GFAP was significantly and negatively related to global 
outcome, whereas 24-hour UCH-L1 was significantly and negatively related to intellectual 
  
x
function and processing speed. Although not statistically significant, relationships with medium 
effects sizes were identified between UCH-L1 and executive function, as well as between GFAP 
and working memory. These results indicate that 24-hour serum UCH-L1 and GFAP are of value 
in predicting functional outcomes 3 months following severe pediatric TBI. 
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Introduction 
Pediatric TBI 
Traumatic brain injury (TBI), broadly defined as a non-congenital, non-degenerative, acquired 
brain injury, is a significant public health concern. Data collected from hospital admissions 
between 1995 and 2001 indicate that approximately 475,000 children are treated annually for 
TBI, with 2,685 cases resulting in death, 37,000 requiring hospitalization, and 435,000 involving 
emergency department visits (Langlois et al., 2005). Due to an underreporting of symptoms and 
the difficulty in determining the number of children seeking treatment outside of hospital 
settings, the sum of these figures is likely an underestimate of total pediatric TBI. 
In addition to associated medical sequelae, TBI may profoundly affect outcomes such as 
cognitive function (Allen et al., 2010; Crowe, Catroppa, Babl, & Anderson, 2012), social, 
emotional, and behavioral function (Ganesalingam et al., 2011), and overall quality of life 
(Limond, Dorris, & McMillan, 2009). In the past it was believed that TBI in children was 
associated with better functional outcomes than in adults due to greater brain plasticity and 
resilience, but it is now recognized that younger age at injury is associated with poorer outcomes 
(Anderson, Catroppa, Godfrey, & Rosenfeld, 2012; Spinella et al., 2003). Skills that are not fully 
developed at the time of injury are at greatest risk of disruption (Catroppa & Anderson, 2011), 
whereas skills that are established prior to injury are relatively spared (Anderson & Catroppa, 
2005; Nadebaum, Anderson, & Catroppa, 2007). In addition, stronger pre-injury cognitive 
function (e.g., higher IQ), higher socioeconomic status, and healthier family function have been 
associated with better functional outcomes following pediatric TBI (Anderson & Catroppa, 2005; 
Anderson et al., 2012). 
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Rapid and accurate assessment of children with TBI is essential for diagnosis, 
classification, prognostication, and treatment. At present, a combination of findings from 
medical history, neurological examination, clinical scales (e.g., Glasgow Comma Scale, GCS), 
and neuroimaging (Bettermann & Slocomb, 2012) is used in clinical assessment. There are, 
however, limitations to this approach, especially in terms of predicting functional outcomes 
(Berger et al., 2002). In addition, prediction of functional outcomes in children with TBI is 
particularly challenging because ongoing developmental changes are occurring within the 
context of disrupted brain structure and function. 
Biomarkers of brain injury are promising tools for improving the prediction of functional 
outcomes. As defined by the National Institutes of Health (Biomarkers Definitions Working 
Group, 2001), a biomarker is “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.” Ideal biomarkers of brain injury should be brain-specific and released 
soon after brain damage, with predictable relationships between biomarker concentration and 
degree of brain injury (Bakay et al., 1983). 
Biomarkers can be found in biofluids such as urine, cerebrospinal fluid (CSF), and blood 
serum. Serum biomarkers have been studied most often in pediatric TBI due to their availability 
and ease of collection (Friess, Kilbaugh, & Huh, 2012). Serum analyses can be completed within 
45 minutes using commercially available assays that require only 0.25 mL of blood. Therefore, 
serum biomarkers are relatively rapid and inexpensive tools with potential as sensitive and 
specific predictors of functional outcomes (Berger et al., 2002). 
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Serum Biomarkers of Brain Injury  
Studies of biomarkers of brain injury have examined a number of proteins, enzymes, protein 
degradation products, cytokines, and micro RNAs (for a review, see Bettermann & Slocomb, 
2012). Research investigating such biomarkers in pediatric populations, of which there is a great 
paucity, is needed for a number of reasons. For example, the developmental changes that occur 
in these biomarkers are very poorly delineated, and there is no information regarding 
developmental changes in serum biomarkers of brain injury following pediatric TBI. In addition, 
as detailed below, the three most commonly-studied biomarkers, S100β, neuron specific enolase 
(NSE), and myelin basic protein (MBP), all have limitations precluding their use in clinical care. 
Given the limitations of these previously investigated biomarkers, the present study focused on 
two novel biomarkers, ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) and glial fibrillary 
acidic protein (GFAP), which show great promise in terms of sensitivity, specificity, and 
prognostication of outcomes following pediatric TBI. 
S100β. The most extensively studied biomarker, S100β, is a calcium-binding protein with 
a low molecular weight that is produced and released primarily by astrocytes in the central 
nervous system (CNS). Serum S100β concentrations do not vary in healthy adults after the age 
of 20 years (Portela et al., 2002). In healthy children, however, age- and sex-dependent changes 
in S100β are characterized by a rapid decrease from birth to 7 years, an increase from 7 to 13 
years, and a subsequent decrease from 14 to 15 years, with generally higher concentrations in 
females (Gazzolo et al., 2003). As these findings demonstrate, extrapolating from adult 
populations precludes a thorough understanding of serum biomarkers in children (Berger, Beers, 
Papa, & Bell, 2012a).  
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With regard to TBI, increases in serum S100β have been identified in adults (Kovesdi et 
al., 2010) and children (Babcock, Byczkowski, Mookerjee, & Bazarian, 2012; Piazza et al., 
2007) following TBI, and higher concentrations have been associated with more severe TBI. 
Serum S100β, however, is not a reliable diagnostic indicator of TBI due to a number of 
limitations, including inadequate specificity. For example, elevations in S100β can occur 
following extracranial trauma such as abdominal injury or long bone fracture, which often co-
occur with TBI (Pelinka et al., 2003; Savola et al., 2003). In addition, because S100β has a serum 
half-life of only 60 to 120 minutes, increases in S100β are transient, with only severe cases 
exhibiting detectable concentrations 12 hours after injury (Berger et al., 2002). 
Neuron-Specific Enolase. NSE, the γ-γ and α-γ dimers of enolase, is a stable glycolytic 
enzyme primarily located in the cytoplasm of neurons. Studies have reported increases in NSE 
following TBI in adults (Kovesdi et al., 2010) and children (Bandyopadhyay, Hennes, Gorelick, 
Wells, & Walsh-Kelly, 2005; Beers, Berger, & Adelson, 2007), with higher concentrations 
associated with more severe TBI. Similar to S100β, there are several limitations which preclude 
the use of NSE as a brain-specific biomarker. Although NSE indicates functional damage to 
neurons, it is also found in adipose tissue, smooth muscle, platelets, erythrocytes, and all 
peripheral and central neuroendocrine cells. Thus, increases in NSE can be indicative not only of 
brain damage but also damage to other types of tissue. 
Myelin Basic Protein. MBP is a lesser studied brain biomarker that plays an important 
role in the myelination of neurons in the CNS. Unlike S100β and NSE, MBP rarely increases 
immediately following brain injury, as serum concentrations peak 48 to 72 hours after injury and 
can remain elevated for up to 2 weeks (Giacoppo et al., 2012; Menascu, Brezner, Tshechmer, & 
Rumeny, 2010). As such, this biomarker is of limited use in the acute stages of brain injury 
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(Beers et al., 2007; Berger et al., 2007). In addition, the use of MBP as a sole marker of TBI is 
limited by its lack of specificity; as a marker of demyelination, elevations in MBP can reflect 
other disease processes such as Alzheimer’s disease and multiple sclerosis (Bettermann & 
Slocomb, 2012). 
Ubiquitin Carboxy-Terminal Hydrolase-L1. UCH-L1 is a novel candidate biomarker 
of neuronal injury which, unlike S100β, NSE, and MBP, is highly abundant in and specific to 
brain tissue, with only minor expression in kidney, skeletal muscle, large intestine, and testes 
(Brophy et al., 2011). Because of its small, globular shape and low molecular weight, UCH-L1 
passes through the blood-brain barrier and into biofluid as an intact protein with no detectable 
breakdown product, thus allowing for rapid detection in blood serum. Whereas serum MBP 
peaks 48 to 72 hours post-TBI, UCH-L1 increases within 6 hours in the CSF of adults following 
severe TBI and remains significantly elevated for at least 168 hours after injury (Papa et al., 
2010). Studies have also shown that UCH-L1 is significantly elevated in children with moderate 
and severe TBI, although children with mild TBI did not exhibit increased UCH-L1, perhaps 
reflecting a lack of neuronal or axonal injury or insensitivity of the assay to mild trauma (Berger 
et al., 2012b). 
Glial Fibrillary Acidic Protein. GFAP is a small monomeric intermediate filament 
protein found in the astroglial skeleton. It is located in both the white and gray matter of the 
brain and is strongly upregulated during astrogliosis (Pelinka et al., 2004). GFAP is not found 
outside the CNS and is believed to indicate cell destruction. CSF (0.016-0.163 ng/mL; 
Rosengren et al., 1992) and serum (0.07 ng/mL; Savage et al., 2011) concentrations of GFAP in 
healthy children have been found to be low. The first study to examine GFAP in children with 
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severe TBI reported elevated serum and CSF GFAP within 24 hours of hospital admission, with 
gradually decreasing concentrations over 7 and 10 days, respectively (Fraser et al., 2011). 
Serum Biomarkers as Predictors of Outcomes following Adult TBI   
There is a general paucity of information regarding relationships between biomarkers of brain 
injury and functional outcomes (Kovesdi et al., 2010) following TBI. That said, S100β, the most 
extensively studied biomarker, appears to reliably predict global outcome in adults with severe 
TBI (Berger, Adelson, Richichi, & Kochanek, 2006a), with increased serum concentrations 
associated with poorer scores on the Glasgow Outcome Scale (GOS; see Appendix A for GOS 
ratings; for a review, see Kovesdi et al., 2010). Findings in mild TBI have been mixed, with 
some studies reporting associations between increased S100β and poorer neuropsychological and 
return to work outcomes (Herrmann et al., 2001; Stranjalis et al., 2004; Waterloo, Ingebrigsten, 
& Romner, 1997) and other studies failing to identify relationships with outcomes (de Boussard 
et al., 2005; Stapert et al., 2005). Studies of other common biomarkers of brain injury have had 
conflicting results that are most likely due to differences in participant inclusion and exclusion 
criteria and sample sizes. 
 Only three studies have investigated the novel biomarkers UCH-L1 and GFAP in relation 
to functional outcomes in adults. In the first study, which included a sample of 81 adults with 
severe TBI, higher 12-hour serum concentrations of UCH-L1 and GFAP were associated with 
more severe injury as assessed by the GCS (Mondello et al., 2011; see Appendix B for GCS 
ratings). In the second study of 41 adults with severe TBI, higher CSF concentrations of UCH-
L1 were associated with greater injury severity, greater 6-week mortality, and poorer 6-month 
outcome on the GOS (Papa et al., 2010). Finally, an investigation of 92 adults with severe TBI 
showed that higher GFAP was related to poorer 3-month outcome on the GOS (Pelinka et al., 
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2004). However, none of these studies examined relationships between either UCH-L1 or GFAP 
and more refined measures of outcome (e.g., neuropsychological function) that may be of greater 
relevance to rehabilitation and long-term function following TBI. 
Serum Biomarkers as Predictors of Outcomes following Pediatric TBI   
Research investigating biomarkers of brain injury as predictors of functional outcomes following 
pediatric TBI is even more limited than the research conducted with adults. Investigations of the 
relationships between elevated serum S100β and outcomes after pediatric TBI have produced 
conflicting findings (Berger, Beers, Richichi, Wiesman, & Adelson, 2007; Piazza et al., 2007; 
Spinella et al., 2003). For NSE, post-traumatic elevations have been associated with poorer 
global (GOS) (Bandyopadhyay, Hennes, Gorelick, Wells, & Walsh-Kelly, 2005; Beers, Berger, 
& Adelson, 2007) and intellectual (Bayley Scales of Infant Development or 2nd Edition and 
Stanford-Binet Intelligence Scale-IV) (Beers et al., 2007) outcomes. Higher peak MBP has also 
been correlated with poorer global outcome (GOS; Glasgow Outcome Scale - Extended Version, 
GOS-E; see Appendix C for GOS-E ratings), whereas higher peak and longer time-to-peak MBP 
have been associated with poorer intellectual function (Bayley Scales of Infant Development, 2nd 
Edition or Stanford-Binet Intelligence Scale-IV) (Beers et al., 2007; Berger et al., 2007). 
Only two studies have been published in which UCH-L1 (Berger, Hayes, Richichi, Beers, 
& Wang, 2012b) and GFAP (Fraser et al., 2011), the novel biomarkers of interest in this study, 
have been examined in relation to global outcomes following pediatric TBI. Turning first to 
UCH-L1, Berger and colleagues (2012b) collected serum UCH-L1 as soon as possible after 
hospital arrival (median of 3.9 hours post-injury) from 39 children younger than 15 years of age 
who had sustained TBI. UCH-L1 concentrations were also obtained from 10 control children 
who presented to the hospital for a well-child examination or evaluation of an acute injury 
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without head trauma. The predictive validity of UCH-L1 was compared with that of S100β, 
NSE, and MBP using concentrations that were previously published by the authors (Berger et al., 
2005; Berger et al., 2006b). Outcome was assessed in the TBI group at hospital discharge and 
three to eight months after discharge using a dichotomized GOS (i.e., good outcome = GOS 1-2, 
poor outcome = GOS 3-5). Results revealed that higher UCH-L1 was associated with poorer 
global outcome. 
 Despite limitations stemming from the single measurement of UCH-L1 and 
dichotomization of the GOS, this study provides support for the use of UCH-L1 in the prediction 
of global outcome following pediatric TBI. Relationships between UCH-L1 and both injury 
severity and outcome were stronger than those for S100β, NSE, and MBP, all of which are of 
limited clinical use. UCH-L1 is an especially promising candidate biomarker of brain injury 
given that it distinguished individuals with TBI from controls soon after injury, an acute stage 
during which mental status can be influenced by alcohol, drugs, and sedation (Papa et al., 2010). 
With regard to GFAP, in children with severe TBI aged 2 to 17 years, Fraser and 
colleagues (2011) reported that higher serum GFAP obtained on the first day of hospital 
admission was correlated with poorer six month global outcome on the Pediatric Cerebral 
Performance Category Scale (PCPC; see Appendix D for PCPC ratings). Furthermore, a serum 
GFAP cutoff of 0.6 ng/mL predicted normal function to moderate disability (PCPC score 1-3) 
with 88% sensitivity and 71% specificity. Although this study was limited to one global outcome 
measure in children with severe TBI, the results clearly indicate that further study is warranted. 
Limitations to Outcome Measures Studied  
As is apparent from the discussion of the aforementioned studies, research on serum biomarkers 
as predictors of outcomes following pediatric TBI has largely employed global outcome 
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measures such as the GOS, GOS-E, Glasgow Outcome Scale – Extended, Pediatric Version 
(GOS-E Peds; see Appendix E for GOS-E Peds ratings), and PCPC. These measures are of 
limited utility because the ratings used are categorical, and in some studies the range of ratings 
has been further restricted through dichotomization. Many studies have also focused on mortality 
as the primary outcome, which has limited utility because it does not provide information to 
families or health care providers regarding recovery or intervention strategies. Overall, there is a 
great need for studies in which biomarkers are examined in relation to more refined outcomes 
based on continuous intellectual and neuropsychological scores rather than categorical global 
ratings.  
 At present, there are no studies in which biomarker concentrations have been related to 
neuropsychological function following pediatric TBI. This dearth of information is especially 
surprising given that there are many neuropsychological deficits associated with pediatric TBI. 
Pediatric TBI is associated with myriad impairments in social (Ganesalingam et al., 2011), 
emotional, behavioral, intellectual (Anderson & Catroppa, 2005; Crowe et al., 2012), academic 
(Kinsella et al., 1995), and cognitive (Catroppa & Anderson, 2011) function, the extent and 
recovery of which are heavily influenced by the severity of injury and age at injury. The most 
common cognitive sequelae following pediatric TBI include problems in attention (Robin, Max, 
Stier, Guenzer, & Lindgren, 1999), memory (Kinsella et al., 1995), processing speed (Kinsella et 
al., 1995), and executive function (Catroppa & Anderson, 2011). 
Specific Aims of the Present Study 
Given the paucity of information available regarding relationships between novel serum 
biomarker concentrations and functional outcomes in children with TBI, the current study was 
conducted with the following specific aims. 
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Specific Aim 1. The first aim was to examine the relationships between 24-hour serum 
biomarker (i.e., UCH-L1 and GFAP) concentrations and global outcome (i.e., GOS-E Peds) three 
months following pediatric TBI. 
Specific Aim 2. The second aim was to examine the relationships between 24-hour serum 
biomarker (i.e., UCH-L1 and GFAP) concentrations and intellectual function as assessed by IQ 
(i.e., Wechsler Abbreviated Scale of Intelligence, WASI), as well as Verbal and Performance IQ, 
three months following pediatric TBI. 
Specific Aim 3. The third aim was to examine the relationships between 24-hour serum 
biomarker (i.e., UCH-L1 and GFAP) concentrations and indices of neuropsychological function 
(i.e., processing speed, working memory, episodic memory, executive function) three months 
following pediatric TBI. 
Specific Aim 4. The fourth aim was to conduct exploratory analyses to examine the 
possible interaction between age and 24-hour serum biomarker (i.e., UCH-L1 and GFAP) 
concentrations in relation to outcomes (i.e., GOS-E Peds, IQ indices, neuropsychological 
indices) three months following pediatric TBI. 
Significance  
This research will enhance our knowledge of pediatric TBI in several crucial ways. First, it is of 
importance to further our understanding of the relationships between 24-hour serum UCH-L1 
and GFAP and global outcome three months following pediatric TBI. Data collected from 
hospital admissions between 1995 and 2001 indicate that approximately 475,000 children are 
treated annually for TBI (Langlois et al., 2005). Current approaches for the diagnosis and 
classification of TBI (e.g., physical exam, CT scan, GCS) suffer from a number of limitations, 
including insufficient prediction of outcome (Berger et al., 2002). A better understanding of the 
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relationships between novel serum biomarker concentrations and global outcome may aid in the 
development of more objective, reliable methods for predicting global outcome. 
 Second, this research will facilitate a better understanding of the relationships between 
24-hour serum UCH-L1 and GFAP concentrations and intellectual and neuropsychological 
function three months following pediatric TBI. Serum biomarkers may be of utility in predicting 
impairments in general intellect, processing speed, working memory, episodic memory, and 
executive function, thus aiding families and health care providers in making better-informed 
decisions in terms of rehabilitation, education, and occupational planning for children with TBI. 
 Finally, this research will provide important information regarding the possible 
interactions between age and 24-hour serum UCH-L1 and GFAP concentrations in predicting 
global, intellectual, and neuropsychological outcomes three months following pediatric TBI. Age 
at injury has been identified as a strong prognostic indictor, with younger injury age associated 
with poorer global outcome (Spinella et al., 2003). In addition, recent research indicates that 
cognitive abilities which are not fully developed are at greatest risk of disruption following brain 
injury (Catroppa & Anderson, 2011), whereas abilities that have reached maturity prior to injury 
tend to remain relatively intact (Anderson & Catroppa, 2005; Nadebaum et al., 2007). However, 
it remains to be determined whether age interacts with 24-hour serum UCH-L1 and GFAP 
concentrations to predict global, intellectual, or neuropsychological outcomes in children. This 
study will provide insight into the value of serum biomarkers as predictors of outcomes in 
children aged 1 month to 17 years and determine whether age and biomarker concentrations 
interact to predict outcomes. 
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Research Design and Methods 
Participants 
A total of 37 children were included in preliminary analyses for the study, all of whom were 
admitted to St. Louis Children’s Hospital with a diagnosis of TBI. 24-hour serum biomarker 
concentrations (i.e., UCH-L1 and GFAP) were available for these 37 children, 33 of whom had 
severe TBI (defined as a GCS score < 9) and 4 of whom had mild TBI (defined as a GCS score > 
12). For three children with mild TBI and three children with severe TBI, no functional outcome 
data were available three months post-injury due to failure to return for assessment; as such, 
biomarker data from these children were not included in final analyses. In addition, because the 
majority of children had severe TBI, only data from children with severe TBI were included in 
final analyses. 
The final sample for data analyses included 30 children. Sample size varied across 
outcome measures due to factors such as participant refusal and physical limitations that 
precluded the completion of some measures. Sample size also varied because intellectual and 
neuropsychological assessments were conducted only with children between 6 and 17 years of 
age. Sample size ranged from 30 children for GOS-E Peds analyses to 11 children for executive 
function analyses. The sample size for GOS-E Peds analyses was consistent with that of pediatric 
TBI studies reporting medium to large effect sizes for correlations between biomarker 
concentrations and global outcomes. No studies have been published in which serum biomarkers 
have been examined in relation to intellectual and neuropsychological outcomes in children 
across the age range of the present study. 
Demographic characteristics of the 30 children in the sample are presented in Table 1. 
Age at injury ranged from 1 to 214 months (M = 125.5, SD = 73.5). The sample comprised 60% 
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male and 20% non-Caucasian children. Regarding injury mechanism, 57% were motor vehicle 
accidents, 20% inflicted injuries, 13% pedestrian accidents, 7% falls, and 3% other injury 
mechanisms. Post-resuscitation GCS score ranged from 3 to 7 (M = 4.4, SD = 1.6). No child had 
a history of intellectual disability, learning disability, CNS disorder (e.g., cerebral palsy), or 
major medical disorder prior to TBI. 
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Table 1. Participant demographics (N=30). 
 
Injury Age 
(mo) 
Injury 
Mechanism GCS 
GOS-E Peds 
(3 mo) Sex Race 
125 mva 3 4 male white 
54 mva 3 6 female black 
17 assault 6 1 female white 
183 mva 3 4 female white 
1 assault 4 6 male white 
175 mva 4 3 female white 
7 assault 5 1 male white 
134 fall 3 6 male white 
56 mva 6 4 male black 
149 pedestrian 3 5 female black 
214 mva 3 4 male white 
206 mva 6 6 female white 
160 pedestrian 3 3 male black 
119 pedestrian 3 2 male black 
1 assault 7 8 male white 
199 mva 5 6 female white 
39 assault 7 1 male white 
41 mva 3 2 female white 
139 mva 5 8 female asian 
117 mva 6 6 male white 
191 pedestrian 3 4 male white 
171 fall 3 6 male white 
191 mva 7 8 male white 
203 mva 3 1 female white 
202 mva 7 5 female white 
4 assault 3 1 male white 
204 mva 6 6 male white 
136 mva 3 6 male white 
138 other 7 8 male white 
190 mva 3 6 female white 
Notes: mo = months; GCS = Glasgow Coma Scale; GOS-E Peds = 
Glasgow Outcome Scale, Extended Pediatric Version; mva = motor 
vehicle accident. 
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Study Measures and Procedures 
Approval to conduct this study was obtained from the Institutional Review Board for the 
Protection of Human Subjects at Washington University in St. Louis. 24-hour serum biomarker 
concentrations were determined and related to functional outcomes three months following 
pediatric TBI. Global outcome was assessed using the GOS-E Peds. Intellectual function (i.e., 
IQ) was assessed using the WASI or WASI-II. Neuropsychological function was measured using 
four indices reflecting the specific cognitive domains of processing speed, working memory, 
episodic memory, and executive function. Intellectual and neuropsychological evaluation 
required approximately three hours for completion. 
Biomarker concentrations. The medical management of children enrolled in the study 
was in accordance with standard clinical care at St. Louis Children’s Hospital, with blood 
samples for biomarker analyses collected within the first 6 hours post-injury and every 24 hours 
thereafter for a maximum of 7 days. Blood samples were processed immediately and stored at -
80°C until the time of biomarker analysis, at which point UCH-L1 and GFAP concentrations 
were measured in collaboration with Banyan Biomarkers, Inc. 
Global outcome. Children underwent evaluations of global outcome three months 
following pediatric TBI using the GOS-E Peds (see Table 2 and Appendix E). The GOS-E Peds 
is a developmentally appropriate, structured scale used to classify younger patients, with 
categories ranging from death (score of 1) to upper good recovery (score of 8). The GOS-E Peds 
is sensitive to severity of injury and recovery over time as measured by parent ratings of daily 
living skills, intellectual function (Bayley Scales of Infant Development, 2nd Edition or Stanford-
Binet-IV), and processing speed (Beers et al., 2012). 
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Table 2. Scores and category labels 
for the GOS-E Peds. 
 
Score Category 
1 Death 
2 Vegetative State  
3 Lower Severe Disability  
4 Upper Severe Disability  
5 Lower Moderate Disability  
6 Upper Moderate Disability  
7 Lower Good Recovery  
8 Upper Good Recovery  
 
Intellectual function. The WASI and WASI-II are brief and reliable batteries comprising 
subtests designed to estimate intelligence in individuals aged 6 to 89 years and 6 to 90 years, 
respectively (Wechsler, 1999; Wechsler, 2011). Administration of two subtests (i.e., Vocabulary 
and Matrix Reasoning) permits estimation of Full Scale IQ, which was used to investigate 
relationships between 24-hour serum biomarker (i.e., UCH-L1 and GFAP) concentrations and 
general intellectual function three months following pediatric TBI. Administration of four 
subtests permits estimation of an individual’s Verbal and Performance IQs, which were used to 
investigate relationships between 24-hour serum biomarker (i.e., UCH-L1 and GFAP) 
concentrations and Verbal and Performance IQs three months following pediatric TBI.  
Vocabulary. The Vocabulary subtest is a measure of expressive vocabulary knowledge 
(Wechsler, 1999). Children named pictures or provided oral definitions of words (e.g., bird, 
tradition, formidable). For all children, the examiner stated the following: “Now, I am going to 
ask you to tell me the meanings of some words. Listen carefully and tell me what each word 
means. Are you ready?” For children aged nine years and older, the examiner pointed to each 
word in a stimulus booklet while pronouncing it so that the child could read along. For children 
aged six to eight years, the stimulus booklet listing each word was not presented. There were a 
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total of 4 picture items and 38 word items. Testing was discontinued after five consecutive 
incorrect responses. 
Similarities. The Similarities subtest is a measure of verbal concept formation and 
abstract verbal reasoning (Wechsler, 1999). Each child’s task was to indicate how objects or 
concepts were alike (e.g., red versus blue, capitalism versus socialism). For children aged six to 
eight years, the examiner stated the following: “Ok, let’s go on. I am going to show you some 
groups of pictures. For each group, I want you to tell me which picture in the bottom row is most 
like the pictures in the top row. Look at these pictures. Which one here is like these?  Show me.” 
For children aged nine years and older, the examiner stated the following: “Okay, let’s go on. In 
this next section, I am going to read two words to you and I want you to tell me how they are 
alike. For example, if I ask, ‘How are cookies and candy alike?’ you would say, ‘They are both 
snacks or food.’” Testing was discontinued after four consecutive incorrect responses. 
Block design. The Block Design subtest is a measure of spatial visualization and abstract 
nonverbal reasoning (Wechsler, 1999). Each child used blocks to replicate two-color designs 
within a specified time limit, with the designs increasing in difficulty from simple designs 
requiring two blocks to more complicated designs requiring nine blocks. For all children, the 
examiner stated the following: “Now, I am going to ask you to make some designs. You see 
these blocks?  They are all alike. On some sides they are all red; on some, all white; and on 
some, half red and half white.” Testing was discontinued after three consecutive incorrect 
responses. 
Matrix reasoning. The Matrix Reasoning subtest is a measure of nonverbal reasoning 
(Wechsler, 1999). Each child viewed a matrix from which a section was missing and completed 
it by indicating one of five response options. For all children, the examiner stated the following: 
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“Now we are going to do something different. I am going to show you some pictures. In each 
picture, there is piece missing. Look carefully at all the pieces of each picture and choose the 
missing piece from the five choices at the bottom of the page. There is only one correct answer 
to each problem. If you believe that more than one answer is right, choose the best one.” The 
examiner then administered two sample items and proceeded to the age-appropriate starting 
point. Testing was discontinued after four consecutive incorrect responses or four incorrect 
responses during five consecutive items. 
Neuropsychological function. Neuropsychological testing included the Wechsler 
Intelligence Scale for Children – 4th Edition (WISC): Digit Span, Coding, and Symbol Search 
subtests; Wechsler Adult Intelligence Scale – 3rd Edition (WAIS): Digit Span, Digit Symbol-
Coding, and Symbol Search subtests; Test of Memory and Learning – 2nd Edition (TOMAL): 
Digits Forward, Digits Backward, Object Recall, and Facial Memory subtests; California Verbal 
Learning Test – Children’s Version (CVLT-C); Developmental NEuroPSYchological 
Assessment – 2nd Edition (NEPSY): Word Generation subtest; Clinical Evaluation of Language 
Fundamentals (CELF) – 3rd or 4th Edition: Concepts & Following Directions subtest; Beery-
Buktenica Developmental Test of Visual-Motor Integration (VMI); Simple Reaction Time, 
Go/No-Go, and Recognition Span computerized tasks. Parents completed the Behavior Rating 
Inventory of Executive Function (BRIEF) and the Conners Parent Rating Scale – Revised, Long 
Version questionnaires. Tests and questionnaires were age-specific such that children of different 
ages may have received different versions. 
 A subset of the tests listed above was used for the present study for several reasons. First, 
as shown in Table 3, combinations of variables from these tests comprised indices reflecting the 
neuropsychological domains of interest (i.e., processing speed, working memory, episodic 
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memory, executive function). For example, the CVLT-C and Facial Memory are clearly tests of 
episodic memory, representing verbal and non-verbal memory, respectively. Second, only for a 
subtest of the tests administered could the performance of children with TBI be compared with 
normative data. For example, for the working memory index, Digit Span Forward and Backward 
were selected because these subtests have normative data, whereas there are no normative data 
for experimental tasks such as Recognition Span. Third, more data were available for some tests 
due to the prioritization of tests within the battery; tests were prioritized because it was expected 
that some children would be unable to complete the entire test session. For example, for the 
episodic memory index, Facial Memory was selected over Object Recall because more children 
completed this test. 
Table 3. Summary of neuropsychological indices. 
  
 
Index Tests Comprising Index 
Processing Speed WISC or WAIS                  Symbol Search 
WISC or WAIS                              
Coding 
Working Memory WISC, WAIS, or TOMAL         Digit Span Forward 
WISC, WAIS, or TOMAL            
Digit Span Backward 
Episodic Memory CVLT-C List A total trials 1-5 
TOMAL                                                 
Facial Memory 
Executive Function CVLT-C Semantic Cluster Ratio 
NEPSY Word Generation                 
Semantic Category Words 
 
Processing Speed Index. The Processing Speed Index from the WISC or WAIS, 
comprising summary scores from the Coding and Symbol Search subtests, was used to assess 
processing speed (Wechsler, 1997; Wechsler, 2003b). Preliminary analyses with data from our 
sample of 30 children with severe TBI showed that standard scores from Coding and Symbol 
Search were significantly correlated (r = .70, p < .01), justifying their aggregation as indicators 
of processing speed. In a study of 43 children aged 6 to 16 years with a history of moderate or 
severe TBI, the Processing Speed Index group mean difference produced the largest effect size, 
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with poorer performance in children with TBI than a healthy control group (Wechsler, 2003b). 
The variable of interest was the Processing Speed Index standard score.  
WISC Coding. Coding is a core processing speed task which involves visual perception, 
visual scanning, and visual-motor coordination (Wechsler, 2003b). Each child copied symbols 
that were paired with simple geometric shapes (if aged six to seven years) or numbers (if aged 
eight years and older) within a specified time limit (Wechsler, 2003a). Using a key, the child 
drew each symbol in its corresponding shape or box. After an instruction and training phase, the 
examiner stated: “When I say go, do these the same way. Start here, go in order, and don’t skip 
any. Work as fast as you can without making mistakes until I tell you to stop. Are you ready?” 
Testing was discontinued when a child completed all of the rows or after 120 seconds, whichever 
came first. The variable of interest was the Coding standard score. 
WAIS Digit Symbol-Coding. Digit Symbol-Coding is a core processing speed task in 
which children copied symbols that are paired with numbers. Using a key, children drew each 
symbol under its corresponding number. After an instruction and training phase, the examiner 
stated: “Now you know how to do them. When I tell you to start, you do the rest of them. Begin 
here and fill in as many squares as you can, one after the other without skipping any. Keep 
working until I tell you to stop. Work as quickly as you can without making mistakes. When you 
finish this line, go on to this one. Go ahead.” Testing was discontinued when a child completed 
all of the rows or after 120 seconds, whichever came first. The variable of interest was the Digit 
Symbol-Coding standard score. 
WISC Symbol Search. Symbol Search is also a core processing speed task which involves 
visual discrimination and visual-motor coordination (Wechsler, 2003b). Children scanned a 
search group and indicated whether a target symbol (if aged six to seven years) or symbols (if 
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aged eight years and older) matched any of the symbols in the search group within a specified 
time limit. After an instruction and training phase, the examiner stated: “When I say go, do these 
the same way. Start here, go in order, and don’t skip any. Work as quickly as you can without 
making mistakes. When you finish the first page, go to the second page and the following page. 
Are you ready?”  Testing was discontinued when a child completed all of the items or after 120 
seconds, whichever came first. The variable of interest was the Symbol Search standard score. 
WAIS Symbol Search. The Symbol Search subtest is a core processing speed task in 
which children visually scanned two groups of symbols (a target group and a search group) and 
indicated whether either of the target symbols matched any of the symbols in the search group. 
After an instruction and training phase, the examiner stated: “When I tell you to start, you do 
these the same way. Begin here and do as many as you can. When you finish the first page, go on 
to the next page and so on. Most people don’t do all of them. Work as quickly as you can without 
changing your answers. Don’t skip any items and don’t stop until I tell you to do so. Any 
questions? Okay. Ready? Begin.” Testing was discontinued when a child completed all of the 
items or after 120 seconds, whichever came first. The variable of interest was the Symbol Search 
standard score. 
 Working Memory Index. The working memory index was assessed using the Digit Span 
subtest (Digit Span total standard score) from the WISC or WAIS, comprising Digit Span 
Forward and Digit Span Backward tasks, or from the TOMAL Digits Forward and Digits 
Backward tasks. Preliminary analyses showed that standard scores from Digits Forward and 
Backward were significantly correlated (r = .70, p < .01). The variable of interest was the 
average of the standard scores from WISC or WAIS Digit Span Forward and Backward or 
TOMAL Digits Forward and Backward. Working memory has been shown to be impaired in 
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children with moderate to severe TBI compared to normative samples using the Digit Span 
Backward task (Conklin, Salorio, & Slomine, 2008).  
WISC Digit Span Forward. Digit Span Forward is a measure of auditory short-term 
memory, attention, concentration, and sequencing skills (Wechsler, 2003b). Each child was 
instructed to repeat numbers in the same order as read aloud by the examiner (e.g., Examiner: 3-
8-2; Child: 3-8-2). For all children, the examiner stated: “I am going to say some numbers. 
Listen carefully, and when I am through, say them right after me. Just say what I say” (Wechsler, 
2003a). Digit Span Forward consists of eight items, each of which is divided into two trials of 
equal span. Testing was discontinued after incorrect responses on both trials of an item. The 
variable of interest was the Digit Span Forward standard score. 
WAIS Digit Span Forward. For all children, the examiner stated: “I am going to say some 
numbers. Listen carefully, and when I am through, I want you to say them right after me. Just say 
what I say” (Wechsler, 1997). Digit Span Forward consists of eight items, each of which is 
divided into two trials of equal span. Testing was discontinued after incorrect responses on both 
trials of an item. The variable of interest was the Digit Span Forward standard score.  
TOMAL Digits Forward. For all children, the examiner stated: “I’m going to say some 
numbers. Listen carefully, because when I’m done, I want you to say them just like I did” 
(Reynolds & Voress, 2007). Digits Forward consists of 15 items. Testing was discontinued when 
a child earned three or fewer points on each of two consecutive items after administration of 
items one through four. The variable of interest was the Digits Forward standard score. 
WISC Digit Span Backward. Digit Span Backward is a measure of auditory short-term 
memory, attention, concentration, sequencing skills, and mental manipulation of information 
(Wechsler, 2003b). Each child was instructed to repeat numbers in the reverse order of that 
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presented by the examiner (e.g., Examiner: 3-8-2; Child: 2-8-3). For all children, the examiner 
stated: “Now I am going to say some more numbers, but this time when I stop, I want you to say 
them backward. If I say 8-2, what would you say?” (Wechsler, 2003a). The examiner 
administered an additional practice trial before proceeding to test items. Digit Span Backward 
consists of eight items, each of which is divided into two trials of equal span. Testing was 
discontinued after incorrect responses on both trials of an item. The variable of interest was the 
Digit Span Backward standard score. 
WAIS Digit Span Backward. For all children, the examiner stated: “Now I am going to 
say some more numbers. But this time when I stop, I want you to say them backward. For 
example, if I say 7-1-8, what would you say?” (Wechsler, 1997). Digit Span Backward consists 
of seven items, each of which is divided into two trials of equal span. Testing was discontinued 
after incorrect responses on both trials of an item. The variable of interest was the Digit Span 
Backward standard score. 
TOMAL Digits Backward. For all children, the examiner stated: “I’m going to say some 
numbers again, but this time when I finish, I want you to say the numbers backward. So if I said 
1-2, what would you say?” (Reynolds & Voress, 2007). Digits Backward consists of 13 items. 
Testing was discontinued after a child earned three or fewer points on each of two consecutive 
items after administration of items one through four. The variable of interest was the Digits 
Backward standard score. 
Episodic Memory Index. The episodic memory index was assessed using a measure of 
immediate verbal recall and a measure of immediate visual recognition memory. The variable of 
interest was the average of standard scores from CVLT-C recall for trials 1-5 and TOMAL 
Facial Memory. Preliminary analyses showed that standard scores from CVLT-C recall and 
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TOMAL Facial Memory were significantly correlated (r = .53, p < .05). Pediatric TBI has been 
associated with poorer verbal memory, as measured by recall on trials 1-5 of the CVLT-C 
(Warschausky, Kay, Chi, & Donders, 2005), as well as poorer nonverbal visual memory (Allen 
et al., 2010).  
CVLT-C trials 1-5. The immediate free recall portion of the CVLT-C was administered 
following standard administration procedures (Delis, Kramer, Kaplan, & Ober, 1994). Children 
were read the directions: “Let’s pretend you are going shopping on Monday. I’m going to read a 
list of things for you to buy. Listen carefully, because when I’m through, I want you to tell me as 
many of the things as you can. You can say them in any order – just say as many of them as you 
can. Are you ready?”  Children then listened as the examiner read a list of 15 words (bananas, 
sweater, puzzle, jacket, grapes, blocks, watermelon, shorts, crayons, peaches, balloons, hat, 
strawberries, belt, marbles) aloud over 5 learning trials, with the words presented in the same 
order for each trial. After each trial, children were asked to freely recall as many words as 
possible. The variable of interest was the standard score for the total number of words correctly 
recalled across all five trials. 
TOMAL Facial Memory. The Facial Memory subtest measures nonverbal, visual memory 
(Reynolds & Voress, 2007). Children were required to recognize and identify faces from a set of 
distracters comprising gray-scale photographs of faces of individuals of various ages, both sexes, 
and various ethnic backgrounds. The examiner began with a practice item, pointing to a picture 
and stating: “See this face?” After a five-second viewing period, the examiner turned the page 
and stated: “Put the chip on the person you saw.” For items with more than one face, instructions 
were modified by saying: “See these faces? Put the chips on the faces you saw.” Children were 
shown 7 pictures of faces and were allowed 5 seconds to view the first 4 stimulus pictures, 10 
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seconds for item 5, 15 seconds for item 6, and 20 seconds for item 7. The variable of interest was 
the Facial Memory standard score. 
 Executive Function Index. The executive function index was assessed by averaging 
standard scores from the CVLT-C semantic clustering variable and the NEPSY Word Generation 
total number of words correctly generated. Preliminary analyses showed that standard scores 
from the CVLT-C and NEPSY Word Generation were not significantly correlated, but the effect 
size for the correlation was medium (r = .39, p < .12). It is likely that small sample size (11 
children with CVLT-C and Word Generation scores) prevented the correlation with medium 
effect size from reaching statistical significance. As such, the aggregate executive function 
variable was retained for further analyses. Executive function, as measured using a word fluency 
task, has been shown to be more impaired in children with severe TBI than in children with mild 
TBI or healthy controls (Levin, Song, Ewing-Cobbs, Chapman, & Mendelsohn, 2001).  
CVLT-C semantic clustering. Semantic clustering is a measure of the extent to which a 
child has “actively imposed an organization on the list of words according to shared semantic 
features. . . a kind of ‘mental filing system’” (Delis et al,. 1994, p. 32). The semantic cluster 
index refers to the ratio of observed to expected correct cluster scores based on the clustering of 
words from the same semantic categories on Trials 1-5 of the CVLT-C. A score of 1 indicates 
chance clustering performance, whereas scores above and below 1 indicate above-chance or 
below-chance clustering performance, respectively. The observed correct semantic cluster score 
refers to the degree to which the child utilizes a semantic strategy (e.g., consecutively recalling 
grapes and bananas from the semantic category fruits) in recalling the list during each of the five 
free-recall trials. The expected correct semantic cluster score refers to the chance value of 
semantic clustering given the total number of words and number of different categories 
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represented in the child’s recall during each of the five free-recall trials. The variable of interest 
was the chance-adjusted semantic clustering standard score for Trials 1-5. 
NEPSY Word Generation semantic category total correct. Word Generation is a subtest 
that measures verbal productivity through the ability to generate words within specific 
categories. Because successful performance requires that children sustain attention, establish, 
maintain, and change response set based on semantic memory, and engage in monitoring and 
self-regulation to avoid repetitive responses, this task is considered a measure of executive 
function. Children were given semantic categories (i.e., animals, food and drinks) and asked to 
name as many items as possible in 60 seconds. Children were read the following directions for 
the animal category: “We want to see how many different animals you can name, like cat or dog. 
Say them as quickly as you can. Are you ready? Go.” Children were read the following 
directions for the food and drink category: “Now, see if you can name some things you can eat or 
drink. Say as many different ones as you can, like pizza or milk. Do it quickly. Ready? Go.” The 
examiner recorded the words in the order produced by children. The variable of interest was the 
semantic category standard score. 
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Data Analyses 
For the most part, raw values for biomarker concentrations were used in data analyses. Similarly, 
raw values were used in analyses involving global outcome (i.e., GOS-E Peds). Standard scores 
(M = 100, SD = 15) based on normative data were used in analyses involving IQ indices, 
neuropsychological indices, and individual neuropsychological tests. 
SPSS 22.0 Software (Chicago, IL) was used to conduct all analyses. Pearson correlation 
was the primary method used to examine the first three aims of the study, in which relationships 
between biomarker concentrations and functional outcomes were examined. Given the a priori 
hypotheses, one-tailed tests were used. Effect sizes were determined using the Pearson 
correlation coefficient, with 0.1 considered small, 0.3 considered medium, and 0.5 considered 
large (Cohen, 1988). Statistical rigor was increased by considering results significant only if p < 
.05 and effect size was either medium or large. Results were considered to represent notable 
trends if effect size was either medium or large. 
For the fourth aim of the study, in which the possible interaction between age and 
biomarker concentrations was examined in relation to outcomes, hierarchical linear regression 
was used. The GOS-E Peds score, IQ, Verbal and Performance IQ, and four indices of 
neuropsychological function (i.e., processing speed, working memory, episodic memory, 
executive function) served as dependent variables in separate analyses for each biomarker. In all 
analyses, age at injury was entered in the first step as an independent variable, biomarker (UCH-
L1 or GFAP) concentrations were entered in the second step, and the interaction between age at 
injury and biomarker concentrations (age at injury X UCH-L1 or age at injury X GFAP) was 
entered in the final step. To reduce multicollinearity, age at injury and biomarker concentrations 
were centered around the mean before creating the interaction terms. 
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 Data were examined carefully in preparation for statistical analyses. For 4 of the 30 
children in the study, the 24-hour serum GFAP concentration was above the range of the assay. 
As such, these four biomarker concentrations were recorded as 50 ng/mL, the upper limit of 
quantification for the GFAP assay. For one child, the 24-hour serum GFAP concentration was 
below the range of the assay. As such, this biomarker concentration was recorded as 0.03 ng/mL, 
the lower limit of quantification for the GFAP assay. 
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Results 
Biomarker Concentrations 
24-hour serum biomarker concentrations of UCH-L1 and GFAP were available for all 30 
children in the study. UCH-L1 ranged from 0.08 ng/mL to 5.10 ng/mL (M = 0.88, SD = 1.34), 
whereas GFAP ranged from 0.03 ng/mL to 50.00 ng/mL (M = 13.37, SD = 16.55). As a group, 
biomarker concentrations were elevated in our sample of children with severe TBI compared 
with concentrations observed in typically developing children (Berger et al., 2012b; Fraser et al., 
2011). The correlation between concentrations of UCH-L1 and GFAP was statistically 
significant, with a large effect size (r = .54, p < .01), indicating that higher UCH-L1 was 
associated with higher GFAP. 
In addition, as shown in Figure 1, UCH-L1 was significantly correlated with age (r = -
.37, p < .05), indicating that UCH-L1 decreased as age increased. It appears that the primary 
reason for this age-related finding is that some younger children have dramatically elevated 
UCH-L1 levels in comparison with older children. This is likely due to differences in injury 
mechanism, as the majority of younger children sustained inflicted injury (6/9), whereas the 
majority of older children sustained injury due to motor vehicle accidents (14/21). The 
correlation between GFAP and age (r = -.29, p < .06) was not significant. 
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Figure 1. UCH-L1 as a function of age. 
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Outcomes 
The range, M, and SD for all functional outcome scores (as well as individual test scores that 
form outcome scores) are presented in Table 4. In terms of global outcome, GOS-E Peds scores 
ranged from 1 to 8 (M = 4.6, SD = 2.3). More specifically, 13% of the children had good 
recovery (GOS-E Peds = 7-8), 39% had moderate disability (GOS-E Peds = 5-6), 24% had 
severe disability (GOS-E Peds = 3-4), 7% were in a vegetative state (GOS-E Peds = 2), and 17% 
died (GOS-E Peds = 1). 
Turning to outcomes indicative of intelligence, IQ ranged from 63 to 111 (M = 88.9, SD 
= 14.3), Verbal IQ ranged from 64 to 106 (M = 87.4, SD = 13.1), and Performance IQ ranged 
from 57 to 116 (M = 89.0, SD = 20.0). In comparison with normative samples, these standard 
scores reflect a broad range of ability across individual children, varying from extremely low to 
high average. At the group level, IQ, Verbal IQ, and Performance IQ all fell within the low 
average range. 
With regard to neuropsychological outcome indices, standard scores for processing speed 
ranged from 53 to 100 (M = 78.3, SD = 16.0), working memory ranged from 55 to 110 (M = 
86.1, SD = 16.1), episodic memory ranged from 63 to 114 (M = 82.3, SD = 15.8), and executive 
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function ranged from 65 to 118 (M = 89.5, SD = 18.4). As was the case for the IQ indices, these 
standard scores reflect a broad range of ability, varying from extremely low to high average. At 
the group level, working memory, episodic memory, and executive function fell within the low 
average range. Processing speed, however, was borderline, suggesting somewhat greater 
difficulty within this neuropsychological domain. 
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Table 4. Range, mean, and standard deviation for GOS-E Peds, IQ, Verbal 
and Performance IQ, neuropsychological indices, and neuropsychological 
test scores. 
 
Outcome Range M SD 
GOS-E Peds (N=30) 1 – 8 4.6 2.3 
IQ (N=15) 63 – 111 88.9 14.3 
    Vocabulary (n=15) 66 – 114 89.4 15.1 
    Matrix Reasoning (n=15) 55 – 117 88.7 19.6 
Verbal IQ (N=13) 64 – 106 87.4 13.1 
    Vocabulary (n=15) 66 – 114 89.4 15.1 
    Similarities (n=13) 58 – 114 83.7 15.5 
Performance IQ (N=13) 57 – 116 89.0 20.0 
    Matrix Reasoning (n=15) 55 – 117 88.7 19.6 
    Block Design (n=13) 58 – 123 88.7 20.4 
Processing Speed (N=12) 53 – 100 78.3 16.0 
    Coding (n=12) 55 – 95 77.1 13.4 
    Symbol Search (n=13) 55 – 115 81.2 19.5 
Working Memory (N=16) 55 – 110 86.1 16.1 
    Digit Span Forward (n=14) 65 – 115 86.1 17.1 
    Digit Span Backward (n=14) 65 – 110 88.6 14.5 
Episodic Memory (N=12) 63 – 114 82.3 15.8 
    CVLT-C Trials 1-5 Recall (n=14) 55 – 112 77.0 21.8 
    Facial Memory (n=14) 70 – 115 88.6 14.1 
Executive Function (N=11) 65 – 118 89.5 18.4 
    CVLT-C Semantic Cluster Ratio (n=14) 70 – 115 89.3 16.0 
    Word Generation (n=11) 55 – 120 87.3 26.7 
Notes: Sample size for the working memory index was larger than sample 
sizes for the constituent tests because, for the two children who completed 
Digit Span from the WAIS-III, normative data were not available that 
separately reflected Digit Span Forward and Backward standard scores. 
Sample size for the episodic memory index was smaller than sample sizes 
for the constituent tests because two children completed CVLT-C recall but 
not Facial Memory and two children completed Facial Memory but not 
CVLT-C recall. 
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There were no significant relationships between age and functional outcome scores. 
There were, however, trends with medium effect sizes between age and Performance IQ (r = -
.45, p < .10) and processing speed (r = -.43, p < .10). As shown in Figures 2 and 3, in each 
instance, outcome scores decreased as age increased.  
Figure 2. Performance IQ as a function of age.
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Figure 3. Processing speed as a function of age.
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Specific Aims 
For each specific aim, findings related to UCH-L1 are presented first, followed by findings 
related to GFAP. 
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Specific Aim 1. As described earlier, the first aim of this study was to examine the 
relationships between 24-hour serum UCH-L1 and GFAP concentrations and global outcome 
(i.e., GOS-E Peds) three months following pediatric TBI. As shown in Table 5, the correlation 
between UCH-L1 and GOS-E Peds at three months post-injury (r = -.27, p < .08) was not 
statistically significant. The correlation between GFAP and GOS-E Peds at three months post-
injury, however, was statistically significant with a large effect size (r = -.53, p < .001); as shown 
in Figure 4, GOS-E Peds decreased as GFAP increased. 
Table 5. Correlations between 24-hour serum biomarker 
(i.e., UCH-L1 and GFAP) concentrations and outcomes. 
 
Outcome Biomarker UCH-L1  GFAP 
GOS-E Peds 
-.27 -.53* 
IQ  
-.59* -.13 
Verbal IQ  -.38 
-.16 
Performance IQ 
-.47 -.12 
Processing Speed  
-.53* -.22 
Working Memory 
-.12 -.34 
Episodic Memory  
-.29 .16 
Executive Function  
-.47 -.24 
Note: * = significant at p < .05 with medium or large 
effect size. 
 
Figure 4. GOS-E Peds as a function of GFAP. 
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Hierarchical regression analyses were used to determine the degree to which GFAP 
predicted losses in GOS-E Peds. Specifically, unstandardized regression coefficients (B) showed 
that for every 1 ng/mL increase in GFAP, GOS-E Peds decreased by 0.073. Extrapolating from 
the mean GFAP concentration of children in our sample, GOS-E Peds decreased by 0.98 in 
relation to increased GFAP, which represents a downward shift of 1 GOS-E Peds category. 
Specific Aim 2. The second aim of the study was to examine the relationships between 24-hour 
serum UCH-L1 and GFAP concentrations and IQ, as well as Verbal and Performance IQ, three 
months following pediatric TBI. As shown in Table 5, there was a significant correlation 
between UCH-L1 and IQ, with a large effect size (r = -.59, p < .01; see Figure 5); although not 
statistically significant, correlations between UCH-L1 and both Verbal (r = -.38, p < .11; see 
Figure 6) and Performance (r = -.47, p < .06; see Figure 7) IQ had medium effect sizes. In all 
instances, intellectual function was poorer as UCH-L1 increased. 
In examining Figures 5 through 7, the UCH-L1 concentration of 3.49 ng/mL appears to 
be an outlier, but this is not the case when considered within the context of the entire sample of 
30 children in the study. Recall that the mean and standard deviation across the entire sample 
were 0.88 and 1.34, respectively. As such, UCH-L1 concentrations would be considered outliers 
when greater than 4.90 ng/mL (i.e., 3 standard deviations from the group mean). In the sample, 
there were four children with UCH-L1 concentrations greater than 3.0 ng/mL. Of these children, 
one had died, one was in a vegetative state, and two had moderate disability; only one of the 
children with moderate disability was able to complete IQ assessment. We elected to retain data 
for this child because exclusion dramatically restricted the range of UCH-L1 and it was of 
interest to evaluate the influence of higher UCH-L1 values on the IQ indices. 
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Turning to GFAP, the correlations with IQ (r = -.13, p < .33), Verbal IQ (r = -.16, p < 
.30), and Performance IQ (r = -.12, p < .36) were not statistically significant. 
Figure 5. IQ as a function of UCH-L1. 
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Figure 6. Verbal IQ as a function of UCH-L1. 
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Figure 7. Performance IQ as a function of UCH-L1. 
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Hierarchical regression analyses were used to determine the degree to which UCH-L1 
predicted losses in standard score points in IQ indices. Specifically, unstandardized regression 
coefficients (B) showed that for every 1 ng/mL increase in UCH-L1, standard scores for IQ, 
Verbal IQ, and Performance IQ decreased by 9.78, 5.38, and 10.23 points, respectively. 
Extrapolating from the mean UCH-L1 concentrations of children in our sample who received 
intellectual evaluation, standard scores for IQ, Verbal IQ, and Performance IQ decreased by 
4.94, 2.45, and 4.65 points in relation to increased UCH-L1. 
Specific Aim 3. The third aim was to examine the relationships between 24-hour serum 
UCH-L1 and GFAP concentrations and indices of neuropsychological function (i.e., processing 
speed, working memory, episodic memory, executive function) three months following pediatric 
TBI. As shown in Table 5, there was a significant correlation between UCH-L1 and processing 
speed, with a large effect size (r = -.53, p < .05; see Figure 8). Given that earlier analyses 
revealed a significant relationship between UCH-L1 and age and a trend for a relationship 
between processing speed and age, a post-hoc regression analysis was conducted in which 
processing speed was entered as the dependent variable, with age followed by UCH-L1 entered 
 38
as independent variables. After accounting for the contribution of age, although not statistically 
significant, a trend with a medium effect size remained for the relationship between UCH-L1 and 
processing speed (r = -.44, p < .12). In addition, although not statistically significant, the 
correlation between UCH-L1 and executive function had a medium effect size (r = -.47, p < .08; 
see Figure 9). Correlations between UCH-L1 and working memory (r = -.12, p < .33) and 
episodic memory (r = -.29, p < .19) were not significant.  
Figure 8. Processing speed as a function of UCH-L1. 
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Figure 9. Executive function as a function of UCH-L1. 
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With regard to GFAP, although not statistically significant, the correlation between 
GFAP and working memory had a medium effect size (r = -.34, p < .10; see Figure 10). 
Correlations between GFAP and processing speed (r = -.22, p < .25), episodic memory (r = .16, 
p < .32), and executive function (r = -.24, p < .25) were not significant. For all findings with 
medium and large effect sizes, neuropsychological function was poorer as biomarker 
concentrations increased. 
Figure 10. Working memory as a function of GFAP. 
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Hierarchical regression analyses were used to determine the degree to which UCH-L1 
and GFAP predicted losses in standard score points in neuropsychological indices. 
Unstandardized regression coefficients (B) showed that for every 1 ng/mL increase in UCH-L1, 
standard scores for processing speed and executive function decreased by 8.81 and 8.57 points, 
respectively. Extrapolating from the mean UCH-L1 concentrations of children in our sample 
who received neuropsychological evaluation, standard scores for processing speed and executive 
function decreased by 4.24 and 5.13 points, respectively, in relation to increased UCH-L1. With 
regard to GFAP, unstandardized regression coefficient (B) showed that for every 1 ng/mL 
increase in GFAP, the standard score for working memory decreased by 0.9 points. Extrapolating 
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from the mean GFAP concentration of children in our sample who received neuropsychological 
evaluation, the standard score for working memory decreased by 6.49 points in relation to 
increased GFAP. 
Additional analyses were conducted to examine relationships between individual 
neuropsychological test scores and 24-hour serum UCH-L1 and GFAP concentrations (see Table 
6). Findings revealed significant correlations between UCH-L1 and Vocabulary (r = -.50, p < 
.05), Matrix Reasoning (r = -.51, p < .05), and Word Generation (r = -.53, p < .05), with large 
effect sizes; although not statistically significant, correlations between UCH-L1 and Block 
Design (r = -.40, p < .09), Coding (r = -.45, p < .08), Symbol Search (r = -.40, p < .09), Digit 
Span Backward (r = -.32, p < .14), and CVLT-C trial 1-5 recall (r = -.37, p < .10) had medium 
effect sizes. Correlations between UCH-L1 and Similarities (r = -.27, p < .19), Digit Span 
Forward (r = .08, p < .40), Facial Memory (r = -.07, p < .41), and CVLT-C semantic cluster ratio 
(r = -.10, p < .37) were not significant. Although no correlations between GFAP and 
neuropsychological test scores were statistically significant, correlations between GFAP and 
Coding (r = -.37, p < .12) and Digit Span Backward (r = -.38, p < .10) had medium effect sizes. 
For all findings with medium and large effect sizes, neuropsychological test performance was 
poorer as biomarker concentrations increased. 
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Table 6. Correlations between 24-hour serum biomarker 
(i.e., UCH-L1 and GFAP) concentrations and 
neuropsychological test scores. 
 
Test Biomarker UCH-L1  GFAP 
Vocabulary  
-.50* -.11 
Matrix Reasoning 
-.51* -.10 
Similarities  
-.27 -.18 
Block Design 
-.40 -.09 
Coding 
-.45 -.37 
Symbol Search  
-.40 .00 
Digit Span Forward .08 -.20 
Digit Span Backward 
-.32 -.38 
CVLT-C Trials 1-5 Recall  
-.37 -.07 
Facial Memory 
-.07 .04 
CVLT-C Semantic Cluster Ratio  
-.10 -.12 
Word Generation  
-.53* -.19 
Note: * = significant at p < .05 with medium or large effect 
size. 
 
Finally, Fisher’s z transformation for dependent overlapping correlations was used to 
determine whether the significant correlations related to aims 1 through 3 (i.e., UCH-L1 and IQ 
and processing speed; GFAP and GOS-E Peds) were different. No result from these analyses 
reached statistical significance, suggesting that the strength of the correlations was similar. 
Specific Aim 4. The fourth aim was to conduct exploratory regression analyses to 
examine the possible interaction between age and 24-hour serum UCH-L1 and GFAP 
concentrations in relation to outcomes (i.e., GOS-E Peds, IQ indices, neuropsychological 
indices) three months following pediatric TBI. As noted previously, both age at injury and 
biomarker concentrations were centered before use in regression analyses. Age at injury centered 
was entered in the first step of all analyses, followed by biomarker concentration centered, 
followed by the interaction between age at injury centered and biomarker concentration centered. 
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Because correlations between age at injury and outcomes, as well as correlations between 
biomarker concentrations and outcomes, were reported earlier, findings from the first two steps 
of the regression analyses are not reported here. 
The interaction between age at injury centered and GFAP centered accounted for a 
significant proportion of the variance in episodic memory (∆R² = .68, ∆F(1, 8) = 19.26, ∆p < 
.005). In addition, there was a trend suggesting that the interaction between age at injury centered 
and GFAP centered accounted for a proportion of the variance in processing speed (∆R² = .26, 
∆F(1, 8) = 3.91, ∆p < .10). To elucidate the nature of the interaction, standard scores for episodic 
memory (see Figure 11) and processing speed (see Figure 12) were plotted as a function of raw 
GFAP concentrations for older versus younger children (based on a median split on age). For 
both neuropsychological outcome indices, standard scores for older children decreased as GFAP 
increased. For younger children, however, standard scores increased as GFAP increased, which 
seems counterintuitive. 
 
 
 
Figure 11. Episodic memory as a function of GFAP 
for younger and older children.
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Figure 12. Processing speed as a function of GFAP 
for younger and older children.
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The reason for this pattern of findings is unclear, but it is possible that age at injury and 
GFAP interact in complex ways to predict functional outcomes. In addition, it should be noted 
that the range of GFAP was restricted in the subsamples of children with episodic memory and 
processing speed standard scores. Specifically, GFAP ranged from 1.13 to 15.57 ng/mL for the 
subsample with episodic memory scores, whereas GFAP ranged from 3.19 to 23.30 ng/mL for 
the subsample with processing speed scores. Recall that GFAP for the entire sample of 30 
children included in the study ranged from 0.03 ng/mL to 50.00 ng/mL. It is possible that the 
restricted range of GFAP resulted in the unexpected patterns of results across older and younger 
children. 
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Discussion  
TBI is a significant public health concern that remains the leading cause of morbidity and 
mortality in children (Langlois et al., 2005). Biomarkers of brain injury that are detectable in 
blood serum are promising new tools for the prediction of functional outcomes following 
pediatric TBI. Previous studies have shown that elevations in the most commonly-investigated 
biomarkers (S100β, NSE, and MBP) are associated with poorer global outcome (Bandyopadhyay 
et al., 2005; Beers et al., 2007; Berger et al., 2007). However, a number of limitations, including 
inadequate specificity to brain injury, preclude the use of these biomarkers in clinical care 
(Berger et al., 2002; Berger et al., 2007; Bettermann & Slocomb, 2012; Pelinka et al., 2003; 
Savola et al., 2003). 
Unlike S100β, NSE, and MBP, the novel biomarkers UCH-L1 and GFAP are specific to 
the brain and exhibit greater sensitivity and specificity in discriminating between adults with TBI 
and healthy adults (Diaz-Arrastia et al., 2014; Missler, Wiesmann, Wittmann, Magerkurth, & 
Hagenstrom, 1999). In children, the only study to compare relationships between outcome and 
UCH-L1, S100β, NSE, and MBP showed that UCH-L1 was the biomarker most strongly 
associated with both global outcome and injury severity (Berger et al., 2012b). In the single 
study investigating GFAP following pediatric TBI, higher GFAP was associated with poorer 
global outcome (Fraser et al., 2011). 
The research conducted to date provides a starting point in determining the utility of 
UCH-L1 and GFAP in predicting functional outcomes following TBI in children, but the focus 
of past research has been on global outcome. In no studies have either UCH-L1 or GFAP been 
examined in relation to intellectual or neuropsychological function. As such, there is no 
information available regarding these novel biomarkers as predictors of general intellectual 
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ability or function within specific cognitive domains. Such information is crucial for guiding 
intervention strategies that may improve cognition and overall quality of life for children with 
TBI. 
The present study was conducted to examine UCH-L1 and GFAP in relation to not only 
global outcome but also intellectual and neuropsychological function following pediatric TBI. 
Serum UCH-L1 and GFAP were measured 24 hours after severe TBI in children aged 1 month to 
17 years. Global outcome was measured three months post-TBI using the GOS-E Peds, whereas 
IQ, Performance IQ, and Verbal IQ were measured three months post-injury using subtests from 
the WASI or WASI-II. Neuropsychological function was measured three months post-injury by 
creating composite indices of processing speed, working memory, episodic memory, and 
executive function based on results from a range of standard neuropsychological tests. In 
addition to investigating relationships between 24-hour biomarker concentrations and the noted 
3-month outcomes, possible interactions between age at injury and biomarker concentrations 
were examined in relation to outcomes. 
Results indicated that both UCH-L1 and GFAP were elevated 24 hours following severe 
pediatric TBI. Consistent with adult research, UCH-L1 was significantly correlated with GFAP 
in children (Mondello et al., 2011). Outcome findings showed that the majority of children in our 
study had global outcome scores on the GOS-E Peds indicative of moderate disability. IQ, 
Performance IQ, and Verbal IQ ranged from extremely low to high average, with group means in 
the low average range, indicating that general intellectual function was slightly poorer than that 
of normative samples. Similarly, neuropsychological indices reflecting working memory, 
episodic memory, and executive function ranged from extremely low to high average, with group 
means in the low average range. For the processing speed index, scores ranged from extremely 
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low to average, with the group mean in the borderline range. The finding of relatively poorer 
processing speed is consistent with reports in the literature of particular impairment in processing 
speed following severe TBI in children (Anderson et al., 2012; Catroppa, Anderson, Morse, 
Haritou, & Rosenfeld, 2007; Wozniak et al., 2007). Impairments in working memory (Mandalis, 
Kinsella, Ong, & Andereson, 2007; Treble et al., 2013), episodic memory (Hawley, Ward, 
Magnay, & Mychalkiw, 2004), and executive function (Levin & Hanten, 2005; Sesma, Slomine, 
Ding, McCarthy, & Children’s Health After Trauma Study Group, 2008) have also been 
observed following pediatric TBI, which is consistent with the current findings. 
Turning to results regarding UCH-L1 and GFAP as predictors of functional outcomes, 
higher GFAP was significantly associated with poorer global outcome, which verifies results 
from the single study of GFAP and global outcome conducted to date (Fraser et al., 2011). In 
contrast, UCH-L1 was not associated with global outcome (r = -.27). In a previous study (Berger 
et al., 2012b), higher UCH-L1 was associated with poorer global outcome (r = .42), which is 
inconsistent with the current finding. Although further research is needed to definitively 
determine the reason for the discrepancy between the studies, it is likely that differences in 
methodology are the cause. For example, Berger et al. examined UCH-L1 4 hours post-injury, 
whereas we examined UCH-L1 24 hours post-injury. Given that UCH-L1 concentrations are 
more elevated within the first 6 than 24 hours post-injury in adults (Mondello et al., 2012), it is 
possible that 4-hour UCH-L1 is a more robust predictor of global outcome than 24-hour UCH-
L1. In addition, Berger et al. used a dichotomized five-category GOS to assess global outcome 
three to eight months post-injury, whereas we used the eight-category GOS-E Peds to assess 
global outcome three months post-injury. Although unlikely, it is possible that scores from the 
GOS are better predicted by UCH-L1 than are scores from the GOS-E Peds due to differences in 
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content. Finally, the sample of children with global outcome data was somewhat larger in the 
Berger et al. study (N = 39) than in the current study (N = 30), which provided Berger et al. with 
greater power to detect a statistically significant correlation. 
With regard to intellectual and neuropsychological function, higher UCH-L1 was 
significantly associated with both poorer IQ and processing speed. In addition, although not 
statistically significant, correlations between UCH-L1 and Verbal IQ, Performance IQ, and 
executive function had medium effect sizes. There were no significant relationships between 
GFAP and either IQ or neuropsychological indices, although the correlation between GFAP and 
working memory had a medium effect size. Overall, these findings suggest that UCH-L1 may be 
the better predictor of intellectual and neuropsychological outcomes, whereas GFAP may be the 
better predictor of global outcome. 
It should be noted that biomarker concentrations were not predictive of outcomes across 
all neuropsychological indices. Episodic memory, for example, was predicted by neither UCH-
L1 nor GFAP. It is possible that the specific conditions of the tests selected to represent episodic 
memory were not optimal. For both the CVLT-C and Facial Memory, immediate recall 
conditions were used, but the more demanding delayed recall conditions may have been better 
choices. The notion that more demanding tests or conditions of tests should be used is supported 
by findings from the working memory index. Correlations between Digit Span Forward and both 
UCH-L1 and GFAP had small effect sizes (r = .08 and r = -.20, respectively), whereas 
correlations between the more demanding Digit Span Backward and both UCH-L1 and GFAP 
had medium effect sizes (r = -.32 and r = -.38, respectively). In addition, in the executive 
domain, CVLT-C semantic clustering was not related to biomarker concentrations, although 
Word Generation (which also has a considerable processing speed component) was related to 
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UCH-L1 with a large effect size. These findings clearly point to the need for future research to 
delineate which cognitive domains and neuropsychological tests are best predicted by biomarker 
concentrations.      
The final issue addressed in the current study was the impact of age at injury on 
biomarker concentrations, outcomes, and the relationships between biomarker concentrations 
and outcomes. Turning first to the relationship between age and biomarkers concentrations, 
UCH-L1 decreased significantly as age increased, whereas GFAP was not significantly related to 
age. The age-related finding for UCH-L1 may have been due to differences in injury mechanism, 
as the majority of younger children sustained inflicted injury, whereas the majority of older 
children sustained motor vehicle accidents. In future research it will be important to determine 
whether UCH-L1 decreases with age regardless of injury mechanism.  
Based on the existing literature, it was hypothesized that younger age at injury would be 
associated with poorer intellectual and neuropsychological outcomes (Ganesalingam et al., 2011; 
Taylor & Alden, 1997). Results from the present study, however, did not support this hypothesis. 
In fact, trends with medium effect sizes suggested that that older age at injury was associated 
with poorer Performance IQ and processing speed. It is possible that the discrepancy in findings 
between past studies and the current study is due to differences in injury mechanism, TBI 
severity, or the timing of outcomes evaluation. Studies reporting age-related deficits in 
intellectual and neuropsychological functions have evaluated outcomes several years post-injury 
(Verger et al., 2000) and with various injury severities (Kaufmann, Fletcher, Levin, Miner, & 
Ewing-Cobbs, 1993), which may have resulted in differing patterns of age-related impairment. 
Unfortunately, examination of this issue is beyond the scope of the current study because only 
 49
three-month outcome data were available for children with severe TBI resulting from a variety of 
injury mechanisms.  
Of particular relevance to the current study, there was only one instance in which the 
interaction between age at injury and biomarker concentration was significantly related to 
outcome. Specifically, the interaction between age at injury and GFAP was significantly 
associated with episodic memory. There was also a trend suggesting that the interaction between 
age at injury and GFAP was associated with processing speed. In both instances, higher GFAP in 
older children was associated with poorer outcome, whereas lower GFAP in younger children 
was associated with poorer outcomes. The discrepancy between older and younger children may 
reflect differences in injury mechanism or small sample size and will require further exploration 
to clarify. 
Overall, findings from the present study suggest that, in general, UCH-L1 may be the 
better predictor of intellectual and neuropsychological outcomes, whereas GFAP may be the 
better predictor of global outcome. However, the relationship between GFAP and 
neuropsychological outcomes may be complex and may need to be considered within the context 
of age at the time of injury. Further research is clearly warranted to investigate novel biomarkers 
of brain injury as predictors of functional outcomes in children with TBI. 
In future research, it will be important to address the limitations of the current study. 
First, and of particular concern, was sample size, which was smaller than expected due to factors 
such as death, withdrawal from the study, and difficulty completing functional outcomes 
evaluations with children having substantial physical limitations and medical comorbidities. It is 
possible that a larger sample size would have permitted detection of additional relationships 
between biomarker concentrations and outcomes. In turn, due to small sample size, it was not 
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possible to conduct analyses on subgroups of children with different injury mechanisms (e.g., 
motor vehicle accident versus inflicted injury) or injuries affecting different brain regions (e.g., 
frontal versus parietal). Second, future studies should consider inclusion of a comparison group 
of demographically-matched children with injuries other than TBI to verify the specificity of 
UCH-L1 and GFAP to pediatric brain injury. Third, in the present study relationships were 
examined only between 24-hour serum biomarker concentrations and 3-month outcomes. It is 
possible that other biomarker variables, such as peak concentrations or time-to-peak 
concentrations (Beers et al., 2007), could be better predictors of outcomes. Similarly, it is 
possible that biomarker concentrations are better predictors of outcomes that are assessed after a 
longer period of time post-injury. Finally, only children with severe TBI were included in the 
current study. Future research including children with mild and moderate TBI is needed to 
determine the value of biomarkers as predictors of outcomes across the range of TBI severity. 
Conclusions 
This was the first study in which serum UCH-L1 and GFAP were examined in relation to global, 
intellectual, and neuropsychological outcomes in children with TBI. Results suggested that 
UCH-L1 was the better predictor of intellectual and neuropsychological outcomes, whereas 
GFAP was the better predictor of global outcome. GFAP, however, may also be a good predictor 
of neuropsychological outcomes if considered within the context of age at the time of injury. 
Additional research will be crucial for translating these findings into clinical care for children 
with TBI. 
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Appendix A 
 
Glasgow Outcome Scale (GOS) 
Score Category 
1 Good Recovery 
2 Moderate Disability (Able to Live Independently, Unable to Return to Work/School) 
3 Severe Disability (Able to Follow Commands, Unable to Live Independently) 
4 Persistent Vegetative State (Unable to Interact with Environment, Unresponsive) 
5 Death 
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Appendix B 
 
Glasgow Coma Scale (GCS) 
Score Feature Responses 
1 
Eye Opening 
None 
2 Opens to Pain, Not Applied to Face 
3 Opens to Verbal Command, Speech, or Shout 
4 Spontaneous, Open with Blinking at Baseline 
1 
Verbal 
None 
2 Incomprehensible Speech 
3 Inappropriate Responses, Words Discernible 
4 Confused Conversation, but Able to Answer Questions 
5 Oriented 
1 
Motor 
None 
2 Extensor (Rigid) Response, Decerebrate Posture 
3 Abnormal (Spastic) Flexion, Decorticate Posture 
4 Withdraws from Pain 
5 Purposeful Movement to Painful Stimulation 
6 Obeys Commands for Movement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 62
Appendix C 
 
Glasgow Outcome Scale, Extended Version (GOS-E) 
Score Category 
1 Upper Good Recovery 
2 Lower Good Recovery 
3 Upper Moderate Disability 
4 Lower Moderate Disability 
5 Upper Severe Disability 
6 Lower Severe Disability 
7 Vegetative State 
8 Death 
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Appendix D 
 
Pediatric Cerebral Performance Category Scale (PCPC) 
Score Feature Responses 
1 Normal Normal, At Age Appropriate Level, School Age Child Attends Regular School Classroom 
2 Mild Disability Conscious, Alert, Able to Interact at Age Appropriate Level School Age Child Attending Regular Classroom, but Grade Inappropriate 
3 Moderate Disability 
Conscious, Sufficient Cerebral Function for Age Appropriate Independent 
Activities, School Age Child Attending Special Education Classroom, May Have 
Learning Disability 
4 Severe Disability Conscious, Dependent for Daily Support Because Impaired Brain Function 
5 Coma or Vegetative State 
Any Degree of Coma Without Any of the Criteria for Brain Death, Unawareness 
(Even if Awake) Without Interaction with Environment, Cerebral 
Unresponsiveness, No Evidence of Cortical Function and Not Aroused by Verbal 
Stimuli, Reflexive Responses, Spontaneous Eye Opening, Sleep-Wake Cycles 
6 Brain Death Apnea or Areflexia or Electroencephalographic (EEG) Silence 
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Appendix E 
 
Glasgow Outcome Scale - Extended, Pediatric Version 
 
Glasgow Outcome Scale-Extended Pediatric (GOS-E Peds) 
________________________________________________________________________________________ 
 
NOTE: Only problems that have developed or become markedly worse since the head injury should be 
considered when completing the GOS-E Peds. That is, the child’s premorbid status must be weighed when 
answering all questions. 
________________________________________________________________________________________ 
 
Information obtained (select one):  In person  By phone  From records 
________________________________________________________________________________________ 
 
1. CONSCIOUSNESS 
 
1a) Is the head-injured person able to obey simple commands or say any words? 
Or for younger patients… 
Can he or she act/react/interact beyond reflexes?    No   Yes (Skip to 2.) 
 
 
 
 
 
 
An individual who shows the ability to obey even simple commands or utter any word or communicate 
specifically in any other way is no longer considered to be in a vegetative state. Eye movements are not reliable 
evidence of meaningful responsiveness; corroborate with nursing staff and the child’s parents when possible. 
Confirmation of VS requires full assessment as in the Royal College of Physician Guidelines. However, for 
infants, actively following the movement of a parent or people/object with eyes, grasping for objects, making 
faces, etc. are interactions; breast feeding and crying continuously can be reflexes. 
________________________________________________________________________________________ 
 
2. INDEPENDENCE IN THE HOME 
 
2a) Is the assistance of another person at home essential every day for some activities of daily living? 
Or for younger patients… 
Is the child dependent upon a caretaker more so than is expected based on age? 
 
 Yes (Go to 2b.)    No (Skip to 3.) 
 
For an older child, complete independence and a ‘no’ answer should mean that the person can get washed, put 
on clean clothes without prompting, prepare food for themselves, deal with callers, and handle minor domestic 
crises. The person should be able to carry out activities without needing prompting or reminding, and should be 
capable of being left alone for an age appropriate period. Young children should be able to accomplish age 
appropriate developmental milestones without assistance (see Vineland Daily Living Skills). If a child 
compensates for physical disability to the point where developmental milestones are only mildly compromised, 
question parents to determine the level of independence (i.e., a child with a hemiparesis who is still able to 
complete tasks that other children of that age can be rated as independent). 
Vegetative State (VS) 
Skip to end of form and record GOS-E 
Peds Score = 2. 
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2b) Does the child need frequent help or for someone to be around at home most of the time? 
Or for younger patients… 
Does the child need frequent help from a caretaker to accomplish tasks that a child this age should be 
able to accomplish (If child sometimes functions at an age appropriate level, then answer ‘yes.’) 
 Yes          No 
 
 
 
 
 
________________________________________________________________________________________ 
 
3. INDEPENDENCE OUTSIDE THE HOME 
3a) Is the child able to shop and travel without assistance? 
Or for younger patients… 
Does the child behave age appropriately outside the home? 
 Yes (Skip to 4.)      No 
 
 
 
 
 
 
This item considers activities such as shopping and traveling, always in the context of age appropriate 
behaviors. This includes being able to plan what to buy, take care of money, and behave appropriately in 
public. The individual need not normally shop, but must be able to do so. A younger child must behave age 
appropriately in public. An older child may drive or use public transit to get around. Ability to use a taxi is 
sufficient, provided the person can phone for it themselves and give instruction the driver. Older children who 
sometimes were allowed to travel independently before the injury should be able to walk to a neighbor’s house, 
take a school bus, ride a bike, or take public transportation. 
________________________________________________________________________________________ 
 
4. SCHOOL/WORK 
 
4a) Can the child function at work or in school at his or her previous capacity? 
 
 Yes (Skip to 5.)    No (Go to 4b.) 
 
If an adolescent was working before the injury, then his or her current capacity for work should be at the same 
level. If the individual was seeking work before, then the injury should not have adversely affected chances of 
obtaining work or the level of work for which he or she is eligible. If the patient was in preschool or a student 
before the injury, then capacity for school work and school activities should not be adversely affected. 
 
4b) Level of restriction: 
i) Able to work only in a sheltered workshop or non-competitive job, in a school setting for severely 
impaired children or tutored at home, or currently unable to work or go to school. 
Yes       No (Go to 4b ii.) 
 
 
 
 
Upper Severe Disability 
Skip to end of form and record GOS-E 
Peds Score = 4. 
 
Lower Severe Disability 
Skip to end of form and record GOS-E 
Peds Score = 3. 
 
Upper Severe Disability 
Skip to end of form and record GOS-E 
Peds Score = 4. 
Lower Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 5. 
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ii) Reduced work or school capacity. 
Yes      No (Go to 5.) 
 
 
 
 
 
______________________________________________________________________________________ 
 
5. SOCIAL & LEISURE ACTIVITIES 
 
5a) Is the child able to resume regular social and leisure activities? 
Yes   (Skip to 6.)   No (Go to 5b.) 
 
The individual may not have resumed all previous leisure activities, but should not be prevented from doing so 
by physical or mental impairment. If he or she has stopped the majority of activities because of loss of interest 
or motivation, then this is considered a disability. For younger children, social and leisure activities can 
include games and toys played with caretakers, siblings or other children as well as the ability to interact in a 
playful manner with others. 
 
5b) What is the extent of restrictions on social and leisure activities? 
 
i) Unable to participate: Rarely, if ever, take part. Yes   No (Go to 5b ii.) 
 
 
 
 
 
 
ii) Participate much less: Less than half as often. Yes   No (go to 5b iii.) 
 
 
 
 
 
 
iii) Participate a bit less: At least half as often as before injury. Yes  No (Skip to 6.) 
 
 
 
  
Upper Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 6. 
Lower Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 5. 
 
Upper Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 6. 
 
Lower Good Recovery 
Skip to end of form and record GOS-E 
Peds Score = 7. 
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6. FAMILY & FRIENDSHIPS 
 
6a) Are there psychological problems that have resulted in ongoing disruption with respect to either family or 
friendships? 
 Yes (Go to 6b.)    No (Skip to 7.) 
 
Typical post-traumatic personality changes: quick temper, irritability, anxiety, aggressive acts, insensitivity to 
others, mood swings, depression, and unreasonable or childish behavior that is not age appropriate. 
 
6b) What is the extent of disruption or strain? 
 
 Constant – daily and intolerable.  
 
 
 
 
 Frequent – once a week or more, but tolerable.  
 
 
 
 
 Occasional – less than weekly.  
 
 
________________________________________________________________________________________ 
7. RETURN TO NORMAL LIFE 
 
7a) Are there any other problems relating to the injury that affect daily life? 
 Yes        No 
 
 
 
 
 
 
Typical problems reported after head injury: headaches, dizziness, tiredness, sensitivity to noise or light, 
slowness, memory failures, concentration problems, or other problems. 
 
Scoring caveat: Remember to consider premorbid status when assigning category scores. To an outcome 
of injury, problems in functioning should have deteriorated from premorbid level. 
 
1 - Death 
2 - Vegetative State (VS) 
3 - Lower Severe Disability (Lower SD) 
4 - Upper Severe Disability (Upper SD) 
5 - Lower Moderate Disability (Lower MD) 
6 - Upper Moderate Disability (Upper MD) 
7 - Lower Good Recovery (Lower GR) 
8 - Upper Good Recovery (Upper GR) 
 
GOS-E Peds Score: _______ 
 
Lower Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 5. 
 
Upper Moderate Disability 
Skip to end of form and record GOS-E 
Peds Score = 6. 
 
Lower Good Recovery 
Skip to end of form and record GOS-E 
Peds Score = 7. 
 
Upper Good Recovery 
Skip to end of form and record GOS-E 
Peds Score = 8. 
 
Lower Good Recovery 
Skip to end of form and record GOS-E 
Peds Score = 7. 
 
